BioTuesdays

Tag - HCW

Harpoon Therapeutics

HCW starts Harpoon Therapeutics at buy; PT $28

H.C. Wainwright launched coverage of Harpoon Therapeutics (NASDAQ:HARP) with a “buy” rating and $28 price target. The stock closed at $13.29 on Jan. 31. Harpoon is advancing a proprietary platform of redirected T cell...

Leap Therapeutics

HCW cuts Leap Therapeutics PT to $3.25 from $7.50

H.C. Wainwright lowered its price target for Leap Therapeutics (NASDAQ:LPTX) to $3.25 from $7.50 after the company decided to re-allocate resources and focus on advancing DKN-01, its anti-Dickkopf-1 antibody, while...

HCW cuts Sunesis Pharma PT to 50 cents from $1.50

H.C. Wainwright lowered its price target for Sunesis Pharmaceuticals (NASDAQ:SNSS) to 50 cents from $1.50, citing a reduction in the probability of success for the vecabrutinib program to 7% from 8%. The stock closed at...

PDS Biotechnology Logo

HCW starts PDS Biotechnology at buy; PT $7

H.C. Wainwright initiated coverage of PDS Biotechnology (NASDAQ:PDSB) with a “buy” rating and $7 price target. The stock closed at $3.05 on Nov. 4. PDS is developing anti-cancer therapeutics leveraging its proprietary...

atyr Pharma

HCW starts aTyr Pharma at buy; PT $8

H.C. Wainwright launched coverage of aTyr Pharma (NASDAQ:LIFE) with a “buy” rating and $8 price target. The stock closed at $3.73 on Nov. 4. aTyr is developing therapies leveraging resokines, naturally occurring...

Stoke Therapeutics

HCW starts Stoke Therapeutics at buy; PT $30

H.C. Wainwright launched coverage of Stoke Therapeutics (NASDAQ:STOK) with a “buy” rating and price target of $30. The stock closed at $22.86. Analyst Debjit Chattopadhyay writes that Stoke is advancing an antisense...

Dynavax

HCW starts Dynavax Technologies at buy; PT $13

H.C. Wainwright initiated coverage of Dynavax Technologies (NASDAQ:DVAX) with a “buy” rating and $13 price target based on an outlook for the sales growth of the company’s marketed hepatitis B vaccine, Heplisav-B. The...

Hookipa Pharma

HCW starts Hookipa Pharma at buy; PT $15

H.C. Wainwright launched coverage of HOOKIPA Pharma (NASDAQ:HOOK) with a “buy” rating and $15 price target. The stock closed at $7.76 on Sept. 26. Hookipa is a developing therapies that leverage its proprietary family...

Bionomics

HCW ups Bionomics to buy; PT to 30 cents from 3 cents

H.C. Wainwright upgraded Bionomics (ASX:BNO) to “buy” from “neutral” and raised its price target to 30c (Australian) from three cents after the company announced results of a pharmacokinetics (PK) study of the tablet...

Tracon Pharmaceuticals Logo

HCW starts TRACON Pharma at buy; PT $2

H.C. Wainwright launched coverage of TRACON Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $2 price target. The stock closed at 57 cents on Aug. 29. TRACON is developing targeted therapeutics for cancer...